Unique ID issued by UMIN | UMIN000031436 |
---|---|
Receipt number | R000035478 |
Scientific Title | Influence of Water Soluble Silicon for Fatty Liver Combined with Lifestyle Related Disease |
Date of disclosure of the study information | 2018/02/23 |
Last modified on | 2019/02/23 22:47:21 |
Influence of Water Soluble Silicon for Fatty Liver Combined with Lifestyle Related Disease
Effect of water-soluble silicon for fatty liver
Influence of Water Soluble Silicon for Fatty Liver Combined with Lifestyle Related Disease
Effect of water-soluble silicon for fatty liver
Japan |
Lifestyle-related disease Combined fatty liver
Hepato-biliary-pancreatic medicine |
Others
NO
To investigate the effect of water-soluble silicon in fatty liver combined with lifestyle-related disease.
Efficacy
Blood pressure measurement, physical measurement, general blood test, blood biochemical test, abdominal ultrasonography, fibrosis marker test, inflammatory marker test, oxidative stress type marker test, adipocytokine type marker test, questionnaire
Interventional
Parallel
Randomized
Cluster
Single blind -participants are blinded
No treatment
2
Treatment
Food |
Approximately 9 ml of water-soluble silicon is drunk for 6 months per day. Diet therapy is also done for drinking intake group.
For non-ingesting group, do not drink it but do only usual diet therapy.
20 | years-old | <= |
Not applicable |
Male and Female
Patients who satisfy any of the following items are targeted.
1: outpatient with lifestyle-related disease
2: Patients complicated with metabolic syndrome
3: Patients complicated with nonmetabolic syndrome and judged as fatty liver by image diagnosis
4: Patients with fatty liver whose other liver injury was denied
Exclude any person who falls under any of the following.
1 Viral hepatitis and liver cirrhosis
2 serious liver dysfunction (liver function test value is more than 3 times normal upper limit)
3 heart failure
4 Severe ketosis or Diabetic coma Type 1 diabetes
5 severe renal dysfunction
6 Severe infection or Patients before and after surgery
7 Patients with a history of hypersensitivity to water-soluble silicon
8 Patients who may be pregnant or pregnant
9 Patients with metabolic liver disease
10 Patients with autoimmune liver disease
11 Patients with cirrhosis /due to causes other than 1
12 When the consent of the patient can not be obtained
13 Case in which the doctor approved inappropriate for participation in the study
30
1st name | |
Middle name | |
Last name | Yoshitaka Fukuzawa |
Aichi Medical University Hospital
Preemptive and Integrative Medicine Center
Karimata 1-1, Yazako, Nagakute city, Aichi Prefecture
0561-62-3311
yofuku@aichi-med-u.ac.jp
1st name | |
Middle name | |
Last name | Yoshitaka Fukuzawa |
Aichi Medical University Hospital
Preemptive and Integrative Medicine Center
Karimata 1-1, Yazako, Nagakute City, Aichi Prefecture
0561-62-3311
yofuku@aichi-med-u.ac.jp
Aichi Medical University Hospital
Aichi Medical University Hospital
Self funding
NO
2018 | Year | 02 | Month | 23 | Day |
Unpublished
Completed
2018 | Year | 02 | Month | 23 | Day |
2018 | Year | 02 | Month | 23 | Day |
2019 | Year | 06 | Month | 30 | Day |
2018 | Year | 02 | Month | 23 | Day |
2019 | Year | 02 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035478
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |